To the best of our knowledge, this was the first study in The Netherlands that compared the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib for EGFR mutation-positive (exon 19 deletion or exon 21 L858R mutation) NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.